From the ∗Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Saint-Cloud

†Beaujon Hospital, AP-HP, Department of Pathology, Clichy

‡Institut Curie, Department of Medical Oncology, Saint-Cloud, France.

Received for publication September 5, 2022; revision accepted January 14, 2023.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Capucine Richard, MD, Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 35 Rue Dailly, 92210 Saint-Cloud, France. E-mail: [email protected].